SIMID First European Provider of Online Full Text Publications

SIMID is the first in Europe to use a single centralized databank to bring scientific-medical full-text publications within easy reach. Through S.M.I.L.E. (Scientific Medical Information Library Europe), medical professionals can search for and download original publications and reviews online, from prominent international peer-reviewed medical scientific journals. Currently, the database contains more than 1000 journals from 28 internationally renowned publishers. S.M.I.L.E. is accessible through www.simid.org and is made possible in part by financial institutions and companies working in the healthcare industry, such as health insurance providers and the pharmaceutical industry.

Investment by the Health Innovation Fund
Recently the Health Innovation Fund I BV has joined SIMID as an investor. This fund is financed from Achmea, OPG, ABN/AMRO and TechnoPartner (the Dutch Ministry of Economic Affairs). "We are proud that this investor has provided us the opportunity to expand our unique product further. By informing medical professionals in Europe about the latest developments within their field, our clients can help them diagnose and treat patients more adequately," comments Boudewijn Gruwel, Director of Marketing & Sales of SIMID.

How does S.M.I.L.E. work?
The medical professional has a customized subscription allowing him free access to the information in S.M.I.L.E. This customized subscription is made possible in part by companies working in the healthcare industry, or financial institutions. "The subscriptions give companies the possibility to provide medical professionals access to the most recent and relevant scientific information," states Boudewijn Gruwel.

S.M.I.L.E. lets users read the latest publications, covering 43 different themes, such as oncology, surgery, cardiology, etc. Users can compile a personal profile and receive automatic alerts when relevant articles become available. The database can also be searched using individual keywords. S.M.I.L.E. is updated daily. The publications containing the listed titles are archived from 2000 on, and all articles can be downloaded as PDF files.

Who is S.M.I.L.E.'s target audience?
The S.M.I.L.E. online database is geared toward health professionals. These might be specialists or general practitioners, but might also be dentists, nurses, or physiotherapists.

About SIMID International B.V.
SIMID stands for the Scientific Institute for Medical Information and Documentation. The goal of SIMID is to provide access to scientific-medical information for health professionals by applying the one-stop-shopping principle. Offering complete publications on a single website creates a unique niche in services to medical professionals and the international healthcare-related industry. Through cooperation with international scientific publishers and the online database S.M.I.L.E., SIMID is the first and only company in Europe able to offer this service to medical professionals. SIMID has branches in the Netherlands and Switzerland. More information can be found at www.simid.org.

About the Health Innovation Fund I BV
The Health Innovation Fund I BV is a venture capital fund established in 2007. It focuses on innovative entrepreneurs providing technological, modernizing solutions and business models for the healthcare industry. Shareholders in this fund are ABN/AMRO, Achmea and OPG. The Health Innovation Fund I BV is administered by Residex, which uses specialized investment funds to offer opportunities to promising and ambitious players in the healthcare sector. More information is available at www.residex.nl.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...